Hospital Formulary Management: The Addition, Removal, and Non-Formulary Request Process

A hospital’s formulary is not a static drug list — it is a governed system, and hospital formulary management is the ongoing decision process that keeps it current: how a drug gets added or removed, how a clinician gets a non-formulary drug approved for a specific patient when nothing on the list fits, and how a pharmacist substitutes within an approved therapeutic class without paging the prescriber every time. The federal floor for all of it is narrow: 42 CFR 482.25(b)(9), the Medicare Condition of Participation for hospital pharmaceutical services, states only that “a formulary system must be established by the medical staff” — it says nothing about how a request moves, what a monograph has to contain, or how interchange or non-formulary decisions get made day to day. That operational detail is what a patient-safety officer, quality director, or risk manager actually has to build, audit, or defend when a decision is challenged.

This guide covers the three linked processes that make the formulary system work in practice: the addition/removal decision path from request to monograph to committee vote, the non-formulary request pathway for individual-patient exceptions, and therapeutic-interchange protocols for shortage- and class-driven substitution. For who sits on the committee, how it votes, and its conflict-of-interest policy, see Pharmacy and Therapeutics (P&T) Committee Charter — that page owns governance; this one owns the decision process itself.

Where This Guide Sits

Three CASRAI pages cover adjacent ground, and it matters which one to reach for:

• P&T committee charter — who votes, quorum, delegation, and conflict-of-interest disclosure. The governance document.
• This guide — how a specific formulary decision actually moves: request, monograph, review criteria, non-formulary exception, and therapeutic interchange.
• Value Analysis Committee — the parallel body most hospitals use for non-drug clinical products (devices, supplies, implants); drugs route through P&T, not value analysis. See also Hospital Supply Chain for how formulary decisions connect to procurement and inventory once a drug is approved.

The Formulary Addition Request: From Submission to Monograph

A formulary addition request typically originates from a prescriber, a pharmacist, or a clinical service noting a therapeutic gap — a new agent with no formulary equivalent, or a class the hospital has never stocked. The request itself is usually a short standardized form: requesting provider, drug name and proposed indication, why an existing formulary agent is inadequate, and anticipated volume of use. That request triggers monograph development, normally done by a clinical pharmacist, which is the actual evidence document the committee reviews. A complete formulary monograph covers:

• Indication and place in therapy — where the drug fits relative to what is already on formulary, not just whether it works in isolation.
• Comparative efficacy and safety — head-to-head or indirect comparison against current formulary alternatives, built from a systematic literature review rather than a single pivotal trial or a vendor-supplied summary.
• Adverse-effect profile and REMS obligations — and specifically how the addition interacts with safeguards the hospital already runs, including its look-alike/sound-alike list and high-alert medications list.
• Cost and pharmacoeconomic assessment — acquisition cost, but also downstream cost impact (monitoring, administration route, length-of-stay effect) where the evidence supports it.
• Anticipated utilization — internal demand estimate and, where available, benchmarking against comparable organizations.

This structure follows the current ASHP guideline on the P&T committee and formulary system (Ciccarello et al., Am J Health-Syst Pharm 2021;78(10):907–918), which frames a formulary decision as needing to be “founded on the evidence-based clinical, ethical, legal, social, logistical, philosophical, quality-of-life, safety, and economic factors” relevant to the drug’s use — deliberately broader than “does it work and what does it cost.” A monograph that answers only efficacy and price is not answering the question the committee is supposed to be asking.

A separate, payer-facing document worth knowing about but not confusing with a hospital monograph: the AMCP Format for Formulary Submissions (version 5.0, April 2024) is the standardized dossier structure manufacturers use to submit evidence to health plans and PBMs for their own formulary decisions. It is a managed-care instrument, not a hospital P&T operating procedure — useful as a reference for what a well-built evidence dossier looks like, but not the document your committee should expect a requesting prescriber to produce.

P&T Committee Review Criteria

At review, the committee is applying the same evidence-based criteria the monograph was built to answer, with three elements worth calling out because they are where a thin review most often shows:

• Literature review, not literature citation. A monograph that lists trials without a synthesized comparative judgment is not doing the work ASHP’s guideline describes — the committee needs an actual “this is comparatively better/worse/equivalent, and here is why” conclusion, not a bibliography.
• Safety interaction with existing safeguards. Adding a drug that shares a look-alike/sound-alike pairing, requires a REMS the hospital has no existing workflow for, or needs a smart-pump library entry is not a reason to reject it automatically — but it is a dependency the committee should see named explicitly, not discover after approval.
• A defined follow-up trigger. Most complete formulary decisions generate a scheduled check-back — commonly a medication use evaluation scoped to confirm the drug is actually being used the way the committee approved it for, not an open-ended addition nobody revisits.

Formulary Removal: A Different Trigger, Not a Mirror-Image Process

Removal decisions rarely start from the same place as additions. The common triggers are distinct enough to warrant naming explicitly:

• Safety signal — a pattern of adverse drug events, a manufacturer safety communication, or an MUE finding that utilization has drifted outside the criteria the committee originally approved.
• Therapeutic obsolescence — a newer agent has clearly superseded the older one on the same criteria the addition used, and stocking both no longer serves a purpose beyond legacy prescribing habit.
• Low or no utilization — the drug was added on an anticipated-demand estimate that did not materialize; carrying it ties up inventory and increases the number of items staff have to know without clinical benefit.
• Manufacturer discontinuation — the decision is forced, and the real work is selecting and communicating the replacement rather than debating whether to remove it.

A removal should generate the same documentation trail as an addition — the criteria applied, the vote, and a communication plan (order-set updates, EHR alerts, staff education) so a removal does not surface first as a stocking surprise on a nursing unit.

The Non-Formulary Request Pathway

Not every unmet need is a formulary-addition question. A non-formulary drug request is patient-specific: a prescriber needs an agent not on the formulary for one patient, right now, and a full monograph-and-committee-vote cycle is the wrong tool for that timeline. Hospitals handle this through a separate, faster pathway that most formulary policies define alongside — but distinct from — the addition process:

• Request and clinical justification. The prescriber documents why no formulary alternative is clinically appropriate for this patient (prior treatment failure, contraindication to formulary options, an indication no formulary agent covers).
• Expedited pharmacist or on-call review rather than a full committee vote — typically a pharmacist applying pre-approved criteria, sometimes with case-by-case sign-off from a P&T chair or designee for higher-risk requests.
• Time-limited, patient-specific approval. The approval covers this admission or a defined course, not an ongoing formulary status — it does not put the drug on the shelf for general use.
• A tracked disposition, because repeated non-formulary requests for the same drug are exactly the signal that should trigger a real addition review rather than staying an indefinitely recurring workaround. A non-formulary log that nobody reviews defeats this purpose.

Getting this pathway wrong runs in both directions: making it too slow pushes prescribers toward informal workarounds that bypass pharmacy review entirely; leaving it permanently open with no volume trigger back to full committee review lets a drug become de facto formulary without ever going through the evidence-based criteria above.

Therapeutic Interchange Protocols

Therapeutic interchange is frequently confused with generic substitution, and the distinction is the one to get right first. Generic substitution is dispensing a different manufacturer’s version of the same active ingredient — governed by state pharmacy law, not a hospital policy decision. Therapeutic interchange is dispensing a different chemical entity within the same therapeutic class — a different statin, a different proton pump inhibitor, a different low-molecular-weight heparin — under a hospital policy the P&T committee has specifically approved in advance. It requires its own authority basis for exactly that reason: nothing in state law makes two different chemical entities interchangeable, so the hospital has to build that authority itself.

That authority runs on two tracks that need to both be in place: the medical staff bylaws (or a P&T-approved policy referenced by them) delegating interchange authority to pharmacy for named drug classes, operating under the same 482.25(b)(9) formulary-system authority the committee itself is chartered under, and — separately — the state’s pharmacy practice act, since not every state authorizes protocol-based substitution by a pharmacist the same way. A hospital cannot assume its interchange policy is enforceable simply because the P&T committee approved it; the underlying state authority has to be confirmed for the state the hospital operates in.

A working interchange protocol, per class, specifies:

• The interchange set — which specific drugs within the class are interchangeable under the protocol, decided using the same evidence-based criteria as a formulary addition (comparative efficacy/safety, not just cost).
• Exclusions. Narrow-therapeutic-index drugs, a documented prior treatment failure or adverse reaction to the alternative, and specific patient populations the evidence doesn’t support are standard carve-outs — interchange protocols are built to exclude these categories, not to be silent on them.
• Prescriber notification — the protocol should specify whether and how the prescriber is notified when an interchange occurs, even though the interchange itself doesn’t require a new order.
• Documentation — the interchange is recorded in the chart as what it is (a protocol-directed substitution), not silently as if the prescriber had ordered the substituted drug directly.
• Discharge reversion. An interchange made for formulary reasons during an inpatient stay is not automatically the right outpatient prescription — discharge medication reconciliation needs to catch this explicitly rather than carrying the inpatient substitute forward by default.

Drug shortages are the most common trigger for an interchange decision made outside the class’s normal review cycle: when a formulary agent becomes unavailable, the committee (or, for a fast-moving shortage, a designated subset acting under delegated authority) has to select and communicate a substitute quickly, using the same safety-first criteria — not defaulting to whatever alternative happens to be in stock without checking it against the exclusions above.

Building the Decision Record

Across all three processes — addition, removal, and interchange — the pattern that holds up under audit or challenge is the same: a documented criteria-based review, a recorded vote or sign-off, and a communication step that reaches the staff who need to act on the decision before it becomes a stocking or ordering surprise. For how that record fits into the committee’s standing agenda, meeting cadence, and conflict-of-interest documentation, see Pharmacy and Therapeutics (P&T) Committee Charter.

Frequently Asked Questions

What is the difference between a formulary addition and a non-formulary request?

A formulary addition puts a drug on the shelf for general use hospital-wide, decided by full P&T committee review against evidence-based criteria. A non-formulary request is patient-specific and time-limited — it approves the drug for one patient’s current course, typically through an expedited pharmacist or on-call review, without changing the formulary itself.

What is therapeutic interchange, and how is it different from generic substitution?

Generic substitution swaps manufacturers of the same active ingredient under state pharmacy law. Therapeutic interchange swaps a different chemical entity within the same drug class, and only happens under a hospital policy the P&T committee has specifically pre-approved for that class — it requires its own delegated authority, not just the pharmacist’s ordinary dispensing discretion.

Does a pharmacist need to contact the prescriber before making a therapeutic interchange?

Not for each occurrence, if the drug pair is inside an approved interchange protocol — that is the point of having one. The protocol should still specify how and when the prescriber is notified, and the interchange must be documented in the chart as a protocol-directed substitution.

What triggers a formulary removal?

The most common triggers are a safety signal (adverse events, a manufacturer safety communication, or an MUE finding), therapeutic obsolescence once a newer agent supersedes it on the same criteria used for the original addition, sustained low utilization, or a manufacturer discontinuation that forces the decision.

Can repeated non-formulary requests for the same drug turn into a formulary addition?

They should be tracked specifically so that pattern is visible — a drug repeatedly requested non-formulary is the practical signal that it may belong on formulary, and that tracking is what routes it back into a full addition review instead of staying an indefinitely recurring workaround.

Who has final authority over a formulary decision?

The medical staff, acting through the P&T committee, under the Medicare Condition of Participation requirement (42 CFR 482.25(b)(9)) that a formulary system be established by the medical staff. The committee’s charter and the medical staff bylaws define how that authority is exercised — voting membership, quorum, and delegation — separately from the decision criteria this guide covers.